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IMPORTANCE Pneumocystis pneumonia (PCP) is a potentially lethal opportunistic infection
that primary prophylaxis can help prevent. The risk of prophylactic therapymust be weighed
against the incidence of PCP in the patient population. Prophylaxis most frequently involves
trimethoprim-sulfamethoxazole, with second-line therapies, including atovaquone, dapsone,
and pentamide. The indication for prophylaxis in immunocompromised patients without HIV
is less well defined. Previously, an incidence of at least 3.5% has been proposed as a cutoff to
justify prophylaxis.
OBJECTIVE To assess the incidence of PCP in patients with autoimmune blistering diseases
receiving no routine prophylaxis.
DESIGN, SETTING, AND PARTICIPANTS This was a retrospective analysis of patientmedical
records to determine the incidence of PCP infections. Themulticenter study was performed
at tertiary care centers that provide care for patients with autoimmune blistering disease in
Germany, Italy, Singapore, Israel, and the Netherlands. Patients had a confirmed diagnosis of
pemphigus vulgaris/foliaceus, bullous pemphigoid, epidermolysis bullosa acquisita, mucous
membrane pemphigoid/cicatricial pemphigoid, or anti-p200 pemphigoid.
MAIN OUTCOMES ANDMEASURES To determine the incidence of PCP defined as patients with
the International Classification of Diseases, Ninth Revision (ICD-9), code 136.3, for PCP, or free
text documentation of PCP occurring based on characteristic radiographic findings with
elevated lactate dehydrogenase, or hospitalization for pneumonia with bronchioalveolar
lavage demonstrating Pneumocystis jiroveci on confirmatory stains.
RESULTS A total of 801 patients with autoimmune blistering diseases were included in this
study; their mean (SD) age was 66.5 (17.6) years, and a total of 465 (58%) were female. Only 1
patient developed PCP, resulting in an incidence rate of 0.1%. This incidence significantly fell
below the recommended threshold of 3.5% (0.1% vs 3.5%, χ21 = 27.0; P < .001). This
incidence was significantly lower than the previously reported incidence of PCP in all
immunosuppressed dermatologic patients (0.1% vs 1.3%; χ21 = 8.2; P = .004).
CONCLUSIONS AND RELEVANCE Routine Pneumocystis prophylaxis for patients with
autoimmune blistering diseases does not seem to be warranted. Patients with autoimmune
blistering disease seem to have a lower risk of PCP than the general population of
immunosuppressed dermatology patients. Risks of routine prophylaxis include hyperkalemia,
hypoglycemia, photosensitivity, thrombocytopenia, andmore rare adverse reactions.
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P neumocystis pneumonia (PCP) is an opportunistic fun-gal infection caused by Pneumocystis jiroveci, for-merlynamedPneumocystis carinii.1Pneumocystispneu-
monia can occur in the setting of human immunodeficiency
virus (HIV), as well as in the setting of congenital or iatro-
genic immunosuppression. Its incidence in patientswithHIV
has been significantly decreased with the use of routine pro-
phylaxis inpatientswithCD4+T lymphocytecountsof less than
2000. Prophylaxis most frequently involves trimethoprim-
sulfamethoxazole,withsecond-line therapies, includingatova-
quone, dapsone, and pentamide. The indication for prophy-
laxis in immunocompromisedpatientswithoutHIV is lesswell
defined.
Meta-analysis of immunocompromisedpatientswithHIV
has suggested aPCP incidenceof at least 3.5% tooutweigh the
risks of therapy.2 These risks include hyperkalemia, hypogly-
cemia, photosensitivity, thrombocytopenia, andmore rare ad-
verse reactions, such as Stevens-Johnson syndrome, agranu-
locytosis, aplastic anemia,drug reactionwitheosinophilia and
systemic symptoms, and fulminant hepatic necrosis. Other
Cochrane meta-analyses of prophylactic trimethoprim-
sulfamethoxazole in immunocompromised patients without
HIV demonstrated that adverse events necessitating the ces-
sation of prophylaxis occurred in 13.8%of patients compared
with 5.9% in patients receiving either placebo or alternative
prophylactic antibiotics.3-5 This results in anumberneeded to
harm of 12.7, although this does not specify severe adverse
events vsminor adverse events.3While primary PCP prophy-
laxis with trimethoprim-sulfamethoxazole was found to im-
prove survival in these patients, it is notable that the inci-
denceofPCP in thiscohortwasestimatedat6.2%.4Thispatient
population included afebrile neutropenic patients, children
with leukemia, andboth solid andbonemarrowtransplantpa-
tients, butnotablydidnot include studiesofpatientswithder-
matologic diseases.
The use of prophylactic treatment in the iatrogenically
immunosuppressed patient is controversial. Some have sug-
gested use or primary prophylaxis for PCP for patients receiv-
ing and equivalent of at least 20 mg of prednisone daily
for more than 4 weeks, particularly if a second risk factor ex-
ists, including malignant neoplasm, interstitial lung disease,
or additional immunosuppressive therapies.6,7 Thedisease in
question, however, plays a significant role in the decision for
Pneumocystis prophylaxis.
Fewstudies have assessed the incidence of PCP inderma-
tologic patients. Lehman andKalaaji8 assessed 150dermatol-
ogy patients receiving immunosuppressive therapy for more
than a month, finding that PCP occurred in 0.5% of patients.
A larger study of 334 patients with immunobullous and con-
nective tissue disease receiving immunosuppressive thera-
piesshowedthat7patients (2%)developedPCP,witha1-month
mortality rate of 43% in those patients.9 Of the patients de-
veloping PCP, only 1 had an immunobullous disease. A Chi-
nesestudy10of202patientswith immunobullousdiseasedem-
onstrated an incidence of PCP in 1.9%. In contrast, an Israeli
study11 of 172 patients following individuals newly diagnosed
as having pemphigus failed to demonstrate any patients
with PCP. Based on these studies, the incidence of PCP in
the dermatologic immunosuppressed population can be esti-
mated at 1.3%.3 PCP carries a significant mortality in these
patients, estimated at 47%.12
Patients with certain diseases carry a greater innate risk
for PCP. For example, granulomatosis with polyangiitis (for-
merly Wegener granulomatosis) is associated with a PCP
incidence of 6%. Therefore, it would be indicated to use pri-
mary PCP prophylaxis in these patients.13 Thus, evidence-
based guidelines must be based on the disease in question
rather than a generalized immunosuppressed state.
Autoimmuneblisteringdisease (AIBD) is characterizedby
circulating autoantibodies targeting epidermal antigens lo-
catedat thebasementmembranezoneor in theepidermis, but
sparing of the vasculature and other organs aswould been in-
volved in connective tissue disease. Patients with AIBD
often require prolonged use of often multiple immunosup-
pressive therapies, putting them at risk for opportunistic
infections.11 Among experts in the treatment of immunobul-
lous disease, there is significant discord in regard to use of
opportunistic infection prophylaxis.14 As such, we sought to
characterize the incidence of PCP in a large cohort of patients
with AIBD to generate evidence-based recommendations
regarding routine PCP prophylaxis in these patients. We hy-
pothesized that patients with AIBDs not receiving routine
prophylaxis fail to reach a PCP incidence of 3.5% and that the
current estimation of 1.3% in all dermatologic patients over-
estimates the incidence of PCP in patients with AIBDs.
Methods
Study Design
A retrospective multicenter study was performed in 6 ter-
tiary referral centers for AIBD. Study populations included
Israel, Germany, the Netherlands, Italy, and Singapore. Rou-
tine use of PCP prophylaxis was not used at these institu-
tions. Following appropriate ethical approval for medical
record review, medical records and/or databases were re-
viewed within each institution.
Key Points
Question Does the incidence of Pneumocystis pneumonia in
patients with immunosuppressed autoimmune blistering disease
not receiving routine prophylaxis fall below the recommended
3.5% incidence suggested to recommend prophylaxis and the
1.3% described in the immunosuppressed dermatology patient
population?
Finding The incidence of Pneumocystis in patients with
immunobullous diseases not receiving routine prophylaxis is 0.1%,
significantly less than the suggested incidence recommended for
initiation of primary prophylaxis and of that previously reported
for immunosuppressed dermatology patients.
Meaning Routine Pneumocystis prophylaxis for patients with
autoimmune blistering diseases does not seem to be warranted
and the incidence is less than that in the overall population of
immunosuppressed dermatology patients.
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Inclusion and Exclusion Criteria
Enrollment timewasdependent on the availability of accurate
medical records (ie, searchableelectronichealth records)orpa-
tient databases at each individual institution. Patients with a
confirmed diagnosis of pemphigus vulgaris and/or foliaceus,
bullous pemphigoid, epidermolysis bullosa acquisita,
mucous membrane pemphigoid and/or cicatricial pemphi-
goid, or anti-p200 pemphigoid were included in the study.
Diagnosis was based on each individual institutions’ protocol
for diagnosing AIBDs, which at a minimum required clinical
suspicion and immunofluorescence studies confirming the
disease in question, with most patients having histologic and
additional serologic confirmation of disease subtype. Patients
without a confirmed disease subtype or paraneoplastic pem-
phigus were excluded. In addition, patients who had received
dapsone at any point during their treatment course, had
received primary Pneumocystis prophylaxis, or had less
than 3 months of follow-up available were excluded. All
patients, regardless of whether they received systemic thera-
pies, were included tominimize selection bias of more severe
presentations, and to account for patients receiving variable
doses of topical steroids, which may have systemic immuno-
suppressive effects. The cohort in the study by Leshem et al11
as well as their method for data extraction has been described
previously.
Power Analysis
Sample size was calculated to be greater than 429 to ensure
an ability to detect an incidence of 1.3%, the reported inci-
denceofPCP indermatologicpatients, comparedwith thepro-
posed 3.5%, with an α error of 0.05 and power of 80%. A sec-
ondarygoal of a samplegreater than718 todeterminewhether
the incidence of PCP in patients with AIBDswas significantly
lower than in all immunosuppressed dermatologic patients,
with an α error of 0.05 and power of 80%. The enrollment
period at each institution is detailed in Table 1.
End Points
Enrollment was considered at the time of the first note writ-
ten in the patient’smedical record in the immunobullous dis-
ease clinic. Thus, outside referrals for poorly controlled dis-
ease or new diagnoses were treated the same, and both were
considered the starting time for enrollment.Follow-upwasde-
fined as the time from the first encounterwithin the clinic up
to themost recent note in themedical record and/or encoun-
ter or death, if recorded. In the case of patients receiving tri-
methoprim-sulfamethoxazole for non-PCP infections, fol-
low-up was stopped at this point.
Patient demographics were extracted, including age, sex,
immunobullousdiseasesubtype,systemicmedicationsusedfor
treating the immunobullousdisease,associatedchroniccomor-
bidities, follow-up time, and the occurrence of Pneumocystis.
Informationonraceorethnicitywasnot routinelyavailable.Co-
morbidities evaluated included diabetes, psoriasis, malignant
neoplasm, and autoimmune diseases, with hypertension and
osteoporosis serving as nonimmunosuppressive comorbidity
controls. Theseweredefined as either International Classifica-
tion of Diseases, Ninth Revision (ICD-9), codes or free text re-
corded chronic comorbidities. The incidence of PCP was de-
fined as patients with the ICD-9 code 136.3 for Pneumocystis
pneumoniaor free textdocumentationofPCPoccurringbased
oncharacteristic radiographic findingswithelevated lactatede-





able information regarding comorbidities were taken into ac-
count. Thus, the incidence of each comorbidity was reported
as incidence of cases inwhich comorbiditieswere available. χ2
Tests were used to compare the incidence of PCP in the study
group comparedwith the proposed cutoff of 3.5% used to jus-
tify prophylaxis, as well as 1.3%, which was the mean inci-
dence of PCP in dermatologic patients from the previously
discussed literature review. Pertinent subgroup analysis of pa-
tients with PCP were additionally performed using a χ2 test to
comparesubgroup incidencewith theproposed3.5%cutoff.All
tests were 2-tailed and performed using the IBM SPSS statisti-
cal software, version 20. P < .05 was considered statistically
significant.
Results
In total, 801 patients met the inclusion and exclusion criteria;
their mean (SD) age was 66.47 (17.62) years, and a total of 465
(58%) were women. Themean follow-up timewas 2.94 years,
resulting in 2354 patient-years. Reasons for exclusion in-
cludeduseofdapsone(258patients), insufficient follow-up(187
patients), andPneumocystisprophylaxis given (6patients).Ad-
ditional demographic information is provided in Table 2. Of
these 801 patients, 1 developed PCP. This patient, aman in his
40swith recalcitrantmucocutaneouspemphigus vulgaris and
no reported comorbidities, was treated with high dose of oral
prednisolone incombinationwithrituximab(givenonceonday
1 and repeated on day 15) according to the rheumatology dos-
ing regimen. Because the patient developed erythema multi-
forme, he was switched to dexamethasone pulse therapy fol-
lowed by oral dexamethasone, 4 mg per day, as described by
Kardaun and Jonkman.15 On day 57 after the first rituximab
dosage he developed PCP. The patient subsequently required
mechanical ventilation and treatment with trimethoprim-
sulfamethoxazole and to date is making a full recovery.
Based on the sample size of 801 patients, an estimated 28
patients (3.5%) would need to develop PCP to justify prophy-
Table 1. A Summary of Participating Institutions’ Enrollment
Institution Enrollment Years
1. Singapore General Hospital, Singapore 2005-2014
2. University of Genoa, Italy 2001-2016
3. Rabin Medical Center, Israel 2003-2012
4. Istituto Dermopatico dell’Immacolata, Italy 1985-2016
5. University Medical Center Groningen, the Netherlands 2002-2016
6. Philipps University, Germany 2004-2016
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laxis. Comparison of the predicted incidence cutoff (3.5%) to
the actual incidence (0.1%) showed χ21 (n = 801) = 27.0
(P < .001). To determine whether our sample was signifi-
cantly lower than that previously reported in the literature for
all dermatologicpatients, theactual incidence (0.1%)wascom-
pared with the previously reported incidence (1.3%) demon-
strating χ21 (n = 801) = 8.2 (P = .004).
A subgroup analysis of the incidence of PCP in patients
receiving rituximab demonstrated an incidence of 1 of 140
(0.7%), which compared with the predicted incidence cutoff
(3.5%) showed χ21 (n = 140) = 3.3 (P = .07). Because patients
with pemphigus often require more significant immunosup-
pression thanpatientswithpemphigoid,weperformeda sub-
group analysis of the 1 of 411 patients with Pneumocystis and
pemphigus (0.2%), which compared with the predicted inci-
dence cutoff (3.5%) showed χ21 (n = 411) = 9.7 (P = .001). An
additional subgroupanalysis excludingpatients receiving topi-
cal steroids, oral tetracyclines, and intravenous immunoglob-
ulindemonstratedan incidenceof 1 of 686 (0.14%),whichwas
also significantly smaller than the proposed 3.5% incidence
cutoff for prophylaxis use χ21 (n = 686) = 21.6 (P = .001).
Discussion
Patients with AIBD might represent a unique group of iatro-
genically immunosuppressed patients. While these patients
typically require prolonged use of often multiple immuno-
suppressive therapies, they may have a lower risk of PCP
compared with other dermatologic conditions requiring iat-
rogenic immunosuppression. Because determining the util-
ity of PCP prophylaxis requires a knowledge of the incidence
of PCP in patients not receiving routine prophylaxis, it is es-
sential to characterize this incidence by disease type.
Our studyof the largest cohort of patientswithAIBDhigh-
lights the relatively low risk of PCP,with the incidence falling
significantly below that of the 3.5% recommended for initiat-
ing PCP prophylaxis.2 In addition, our study was sufficiently
powered to demonstrate that the incidence of PCP in all
dermatologic patients (1.3%) significantly overestimated the
incidence inpatientswithonly immunobullousdiseases.Thus,
theuseof routineprophylaxisagainstPCPinpatientswithAIBD
could not be supported by our data.
Because only 1 patient developed PCP, we could not de-
fine clear risk factors from our study. This patient developed
PCP while receiving both high-dose oral glucocorticoids and
after receiving rituximab.Hedidnothave anyunderlyingpul-
monaryabnormalities, lymphopenia,orneutropenia. Inastudy
of Chinese patientswithAIBD, thosewhodeveloped PCPhad
absolute lymphocyte counts ranging from 330 to 1200/μL.10
This might indicate that routine laboratorymonitoring could
identifypatientswith lymphopenia, promptingeither a switch
in immunosuppressive therapy, or temporary PCP prophy-
laxis. Likewise, in a review of all reported cases of PCP devel-
oping in dermatology patients, Gonzalez Santiago et al12 de-
scribed 7 patients who developed PCP, 6 of whom had either
lymphopenia,malignantneoplasm,orpulmonary fibrosis and
1withoutadescriptionof comorbidities.All of theseareknown
risk factors for PCP, particularly lymphopenia.
Limitations
Our studyhas several limitationsowing to its retrospectivena-
ture. Identification of diagnoses was based on medical rec-
ords and database review. Multiple criteria to confirm the di-
agnosis of PCP were chosen to increase the sensitivity for
identifying thisdiagnosis.Themedical recordsofpatientswho
received treatment prior to their referral to tertiary AIBD cen-
terswere reviewed for history of pneumonias to avoidunder-
estimation of PCP cases. Cases of pneumonia and atypical
pneumonia were all analyzed to ensure that patients did not
receive treatment for PCPbut rather receivedantibiotics, such
asmacrolidesor cephalosporins. Still, given that thestudycap-
tures patients froman initial visit to a tertiary care centerwith
a minimum of 3 months of follow-up, there is a potential for
underestimation.Thismay,however, bebalancedby themore
severe cases treated in a tertiary care center. Determining du-
ration, treatment courses, or extent of concomitant use of dif-
ferent medication doses could not be performed to further
stratify the level of immunosuppression inourpopulationbe-
cause information frompreviousmedical record systemswas
Table 2. Demographics of 801 PatientsWith Autoimmune Blistering
Disease Included in the Present Study
Total Sample Size No. (%)
Follow-up, mean (SD), y 2.94 (3.25)
Age, mean (SD), y 66.47 (17.62)
Female sex 465 (58.0)
Disease subtype
Pemphigus foliaceus 51 (6.4)
Pemphigus vulgaris 360 (44.9)
Bullous pemphigoid 322 (40.2)
Epidermolysis bullosa acquisita 13 (1.6)
Mucous membrane pemphigoid 54 (6.7)
Anti-p200 pemphigoid 1 (0.1)
Medications received






Intravenous immunoglobulin 34 (4.2)




Diabetes mellitus 175 (22.9)
Osteoporosis 49 (7.9)
Psoriasis 10 (1.6)
Malignant neoplasm 59 (9.7)
Autoimmune disease 45 (7.3)
Pneumocystis incidence
3 mo from initial presentation 1 (0.1)
a Percentage based onmedical records in which comorbidities were available.
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summarized in binary form when integrated into newer elec-
tronic medical records or databases. Thus, a patient who re-
ceivedsimultaneousprednisoneandmycophenolatecouldnot
be routinely differentiated from a patient receiving predni-
soneandthen later requiringmycophenolate.Furtherprospec-
tive evaluation accounting for the degree of immunosuppres-
sion (eg, treatment courses, concomitant therapies) would be
beneficial forcomparisonwithother immunosuppressedstates.
Thisparticularly is true for theuseof topical corticosteroidsbe-
causeapatientwhoreceiveddailywhole-bodyclobetasolwould
not be considered to be on systemic immunosuppression, de-
spite the significant level of systemic immunosuppression that
occurswith thisprotocol.16Tocounter this, allpatientswith im-
munobullous disease, whether receiving systemic immuno-
suppression,were included in thestudy.Still, a subgroupanaly-
sis was performed of patients receiving only systemic
immunosuppressive therapy, and our findings of low PCP in-
cidencewere not changed even in this high-risk cohort. In ad-
dition, the exclusion of patients prescribed dapsone de-
creased the number of patients assessed. Our study was




was performed at tertiary and quaternary care centers, where
moreaggressivetherapiesmaybeusedthanincommunityprac-
tice. The inclusion of patients from2 continents and6 centers,
however, improves the generalizability to the larger cohort of
patients with AIBDs.
Conclusions
The high mortality of PCP warrants significant discussion in
regard toprophylaxis;however, the incidenceofPCP in thedis-
easepopulationmust surpass the risksofprophylactic therapy.
Wedemonstrate ina large,multinationalcohortofpatientswith
AIBDs that the incidence of PCP does not pass muster. Thus,
even in patients with immunobullous disorders receiving
various systemic immunosuppressive therapies in the rou-
tineclinical setting, lackofprophylaxiswasnotassociatedwith
a sufficient incidence of PCP to warrant prophylaxis.
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